biology · global
Orviglance Faces FDA Hold-Up as Dispute Shifts From the Drug Itself to Image Reading
After Ascelia’s application for its liver MRI contrast agent received a complete response letter from the FDA, the latest explanation points the regulatory focus toward the clinical image-reading process; this leaves the company room for further dialogue, while also underscoring that in reviews of diagnostic drugs, how data are generated and interpreted is equally critical.
Whether a diagnostic drug can reach the market is not answered only by its chemical formula or safety data. It also depends on how images are acquired, who reads them, and whether the reading results can be reproduced. Swedish pharmaceutical company Ascelia Pharma recently received a U.S. FDA complete response letter for the new drug application for Orviglance, meaning the regulator cannot approve it for now based on the existing data. But the latest update suggests the dispute may center on the clinical trial image-reading process, rather than a straightforward rejection of the product concept.
Orviglance is an oral contrast agent for liver MRI, with a target population that includes patients with impaired kidney function who are less suitable for gadolinium-based contrast agents. On July 3, Ascelia said the FDA had requested additional clinical data and supplementary product documentation. On July 12, the company further explained that this update was in response to the FDA’s disclosure of the complete response letter, and said the clinical concerns were related to the image-reading procedure.
The key point in the company’s explanation is that the pivotal SPARKLE trial used the originally planned MRI sequences; after problems emerged with the early readers, Ascelia introduced a new independent, blinded image re-read procedure. This framing suggests the company wants to define the issue as one of data interpretation and review methodology, rather than a comprehensive failure of the trial design. However, public information remains limited, and it is not yet possible from the outside to determine whether the “additional clinical data” requested by the FDA would require a new trial, supplementary analyses, or could be answered by reorganizing existing imaging data.
A complete response letter in drug review does not amount to a permanent rejection, but it does force the company back to the regulatory negotiating table. Ascelia said it is preparing to hold a Type A meeting with the FDA. Such meetings are typically used to address key disagreements after a rejection, with the aim of clarifying what data the regulator truly needs and whether a faster resubmission pathway exists. The company also said some issues involve product documentation and are expected to be handled in the near term; if this is true, the difficulty may be lower than recruiting patients again for a large clinical trial.
The market reaction showed that investors did not view the response letter as a minor episode. Swedish media outlet Omni reported that after the news was announced, Ascelia’s share price plunged by more than 70% on the Stockholm exchange; CEO Magnus Corfitzen said the company would work with the FDA to find the fastest path forward. For a company whose main expectations rest on a single late-stage asset, an extended regulatory timeline directly translates into cash burn and financing pressure. Ascelia previously said its cash could support operations into 2027 and that it would assess possible cost-saving measures.
This case is also a reminder that clinical evidence for diagnostic products is often more fragile than generally imagined. Therapeutic drugs usually establish benefit through patient survival, symptoms, or changes in biomarkers. Contrast agents, by contrast, depend heavily on image quality, consistency of interpretation, and clinical interpretability. If the image-reading process has flaws, even if the same set of images still exists, regulators may question whether the results are sufficient to support marketing approval.
The next key issue is not whether the company can describe Orviglance in more optimistic language, but whether the FDA, after the Type A meeting, will accept a re-read, supplementary analyses, or documentation revisions as a way to resolve the problem. If the answer leans toward requiring new clinical data, both time and capital costs will rise. If the dispute is mainly limited to image reading and product documentation, Orviglance may still retain a shorter resubmission path. What can be said with certainty at this stage is that this application has moved from the single-track question of “whether the product is effective” to the regulatory test of “whether the evidence is sufficiently credible.”